y777
From sex drive woes to cheating and porn addiction, Dear Deidre reveals readers’ most common problems of 2024
(The Center Square) - California Gov. Gavin Newsom said if President-elect Donald Trump ends the $7,500 electric vehicle rebate program, he’ll get Californians to pay for new credits. However, the credits would not include Tesla, which is the most popular EV company and the only EV manufacturer in the state. This comes weeks after Newsom and his administration passed new refinery and carbon credit regulations that will add up to $1.15 per gallon of gasoline and require Californians with gasoline-powered cars to earn up to another $1,000 per year in pretax income to afford. “We will intervene if the Trump Administration eliminates the federal tax credit, doubling down on our commitment to clean air and green jobs in California,” said Newsom in a statement. Tesla CEO Elon Musk, whose rocket launches were recently blocked by a California regulatory board that cited his personal politics, shared his disapproval on his social media platform, X, after Newsom staff told Bloomberg that Tesla models would not qualify for California rebates. “Even though Tesla is the only company who manufactures their EVs in California,” said Musk. “This is insane.” Musk recently moved SpaceX and X out of California, citing a new law signed by Newsom banning parental notification for gender change requests from K-12 students. The credits would be paid for through California’s cap-and-trade program, which requires carbon emitters to purchase credits from the state — costs which are generally passed on to consumers in the form of more expensive gasoline, energy, and even concrete. Emitters buy a few billion dollars worth of credits from California each year, with the state’s $135 billion high speed rail project getting the lion’s share of the revenue. The California Resources Board — all but two of whose voting members are appointed by the governor — recently approved $105 billion in EV charging credits and $8 billion in hydrogen charging credits to be largely paid for by drivers of gas cars and diesel trucks. An investigation by The Center Square found the change was pushed by EV makers and the builders of EV charging systems. Buyers of EV chargers, who pay for the energy and own the charger, sign installation contracts that permanently give away their rights to government or other EV charging credits generated from fueling a vehicle with electrons instead of gasoline. These chargers are often bundled with the purchase of an EV, or covered entirely by utility or government rebates, meaning they are permanent, zero-or-low-cost revenue streams for the company collecting the credits.NoneDavid Bonderman, co-founder of private equity firm TPG and co-owner of Seattle Kraken, dies at 82
NEW DELHI: E-commerce company Snapdeal has managed to cut down its loss to Rs 160.38 crore in FY24 from Rs 282.20 crore in FY23. Apart from this, the company's Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) loss declined by 88 per cent to Rs 16 crore in FY24. It was Rs 144 crore in FY23. The reason for the reduction in the company's loss is the decline in expenses. The company's total expenditure in FY24 was Rs 540.76 crore. It was Rs 687.93 crore in FY23. The employee benefits expenditure of the company in FY24 declined by 48.5 per cent on YoY (year-on-year) basis to Rs 158.4 crore. It was Rs 307.53 crore in FY23. During this period, the company's advertising expenditure was reduced by 23.5 per cent on YoY basis to Rs 70.37 crore. Snapdeal's operating income increased by 2.1 per cent to Rs 379.76 crore in FY24 from Rs 371.96 crore in FY23. Market services have the biggest contribution of Rs 252.55 crore to the company's revenue. However, it decreased by 9.6 percent on YoY basis as compared to FY23. The company's enablement income increased by 14.8 per cent year-on-year to Rs 103.36 crore in FY24. The company's income from other items has increased 8 times to Rs 23.85 crore in the last financial year. According to the stock exchange filing, Snapdeal has reduced its stake in Unicommerce. The company had raised Rs 33 crore from the secondary sale of 3.4 per cent stake during May-June 2024 ahead of the IPO and Rs 81 crore from the sale of 9.2 per cent stake under the offer for sale in the IPO that came in August 2024. Snapdeal is one of India’s leading e-commerce platforms. Founded in 2010, Snapdeal focuses on the value commerce market in India and has served more than 10 Crore online shoppers over the past 14+ years.None
WASHINGTON (AP) — Donald Trump’s personnel choices for his new Cabinet and White House reflect his signature positions on immigration and trade but also a range of viewpoints and backgrounds that raise questions about what ideological anchors might guide his Oval Office encore. With a rapid assembly of his second administration — faster than his effort eight years ago — the former and incoming president has combined television personalities , former Democrats, a wrestling executive and traditional elected Republicans into a mix that makes clear his intentions to impose tariffs on imported goods and crack down on illegal immigration but leaves open a range of possibilities on other policy pursuits. “The president has his two big priorities and doesn’t feel as strongly about anything else — so it’s going to be a real jump ball and zigzag,” predicted Marc Short, chief of staff to Vice President Mike Pence during Trump’s 2017-21 term. “In the first administration, he surrounded himself with more conservative thinkers, and the results showed we were mostly rowing in the same direction. This is more eclectic.” Indeed, Secretary of State-designee Marco Rubio , the Florida senator who has pilloried authoritarian regimes around the world, is in line to serve as top diplomat to a president who praises autocratic leaders like Russia’s Vladimir Putin and Hungary’s Viktor Orban. Republican Rep. Lori Chavez-DeRemer of Oregon has been tapped to sit at the Cabinet table as a pro-union labor secretary alongside multiple billionaires, former governors and others who oppose making it easier for workers to organize themselves. The prospective treasury secretary, Scott Bessent , wants to cut deficits for a president who promised more tax cuts, better veterans services and no rollbacks of the largest federal outlays: Social Security, Medicare and national defense. Abortion-rights supporter Robert F. Kennedy Jr. is Trump's choice to lead the Health and Human Services Department, which Trump’s conservative Christian base has long targeted as an agency where the anti-abortion movement must wield more influence. Former Republican House Speaker Newt Gingrich allowed that members of Trump’s slate will not always agree with the president and certainly not with one another. But he minimized the potential for irreconcilable differences: “A strong Cabinet, by definition, means you’re going to have people with different opinions and different skills.” That kind of unpredictability is at the core of Trump’s political identity. He is the erstwhile reality TV star who already upended Washington once and is returning to power with sweeping, sometimes contradictory promises that convinced voters, especially those in the working class, that he will do it all again. “What Donald Trump has done is reorient political leadership and activism to a more entrepreneurial spirit,” Gingrich said. There's also plenty of room for conflict, given the breadth of Trump's 2024 campaign promises and his pattern of cycling through Cabinet members and national security personnel during his first term. This time, Trump has pledged to impose tariffs on foreign goods, end illegal immigration and launch a mass deportation force, goose U.S. energy production and exact retribution on people who opposed — and prosecuted — him. He's added promises to cut taxes, raise wages, end wars in Israel and Ukraine , streamline government, protect Social Security and Medicare, help veterans and squelch cultural progressivism. Trump alluded to some of those promises in recent weeks as he completed his proposed roster of federal department heads and named top White House staff members. But his announcements skimmed over any policy paradoxes or potential complications. Bessent has crusaded as a deficit hawk, warning that the ballooning national debt , paired with higher interest rates, drives consumer inflation. But he also supports extending Trump’s 2017 tax cuts that added to the overall debt and annual debt service payments to investors who buy Treasury notes. A hedge-fund billionaire, Bessent built his wealth in world markets. Yet, generally speaking, he’s endorsed Trump's tariffs. He rejects the idea that they feed inflation and instead frames tariffs as one-time price adjustments and leverage to achieve U.S. foreign policy and domestic economic aims. Trump, for his part, declared that Bessent would “help me usher in a new Golden Age for the United States.” Chavez-DeRemer, Trump promised, “will achieve historic cooperation between Business and Labor that will restore the American Dream for Working Families.” Trump did not address the Oregon congresswoman’s staunch support for the PRO-Act, a Democratic-backed measure that would make it easier for workers to unionize, among other provisions. That proposal passed the House when Democrats held a majority. But it’s never had measurable Republican support in either chamber on Capitol Hill, and Trump has never made it part of his agenda. When Trump named Kennedy as his pick for health secretary, he did not mention the former Democrat’s support for abortion rights. Instead, Trump put the focus on Kennedy’s intention to take on the U.S. agriculture, food processing and drug manufacturing sectors. The vagaries of Trump’s foreign policy stand out, as well. Trump's choice for national security adviser , Florida Rep. Mike Waltz, offered mixed messages Sunday when discussing the Russia-Ukraine war, which Trump claims never would have started had he been president, because he would have prevailed on Putin not to invade his neighboring country. Speaking on “Fox News Sunday,” Waltz repeated Trump’s concerns over recent escalations, which include President Joe Biden approving sending antipersonnel mines to Ukrainian forces. “We need to restore deterrence, restore peace and get ahead of this escalation ladder, rather than responding to it,” Waltz said. But in the same interview, Waltz declared the mines necessary to help Ukraine “stop Russian gains” and said he’s working “hand in glove” with Biden’s team during the transition. Meanwhile, Tulsi Gabbard, Trump’s pick for director of national intelligence , the top intelligence post in government, is an outspoken defender of Putin and Syrian President Bashar al Assad, a close ally of Russia and Iran. Perhaps the biggest wildcards of Trump’s governing constellation are budget-and-spending advisers Russell Vought, Elon Musk and Vivek Ramaswamy. Vought led Trump’s Office of Management and Budget in his first term and is in line for the same post again. Musk, the world’s wealthiest man, and Ramaswamy, a mega-millionaire venture capitalist, are leading an outside advisory panel known as the “Department of Government Efficiency.” The latter effort is a quasi-official exercise to identify waste. It carries no statutory authority, but Trump can route Musk’s and Ramaswamy’s recommendations to official government pathways, including via Vought. A leading author of Project 2025 , the conservative movement’s blueprint for a hard-right turn in U.S. government and society, Vought envisions OMB not just as an influential office to shape Trump’s budget proposals for Congress but a power center of the executive branch, “powerful enough to override implementing agencies’ bureaucracies.” As for how Trump might navigate differences across his administration, Gingrich pointed to Chavez-DeRemer. “He might not agree with her on union issues, but he might not stop her from pushing it herself,” Gingrich said of the PRO-Act. “And he will listen to anybody. If you convince him, he absolutely will spend presidential capital.” Short said other factors are more likely to influence Trump: personalities and, of course, loyalty . Vought “brought him potential spending cuts” in the first administration, Short said, “that Trump wouldn’t go along with.” This time, Short continued, “maybe Elon and Vivek provide backup,” giving Vought the imprimatur of two wealthy businessmen. “He will always calculate who has been good to him,” Short said. “You already see that: The unions got the labor secretary they wanted, and Putin and Assad got the DNI (intelligence chief) they wanted. ... This is not so much a team-of-rivals situation. I think it’s going to look a lot like a reality TV show.”NoneWARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") WINT , a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities," said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements," Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization." Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company's Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company's common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient's condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF)." The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff") of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q") for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov . Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.com WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2024 December 31, 2023 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 2,300 $ 4,319 Prepaid expenses and other current assets 1,628 1,060 Total current assets 3,928 5,379 Property and equipment, net 128 183 Restricted cash 9 150 Operating lease right-of-use assets 1,133 1,444 Intangible assets 25,250 25,250 Total assets $ 30,448 $ 32,406 LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 2,054 $ 809 Accrued expenses 1,650 1,618 Operating lease liabilities - current portion 468 436 ELOC commitment note payable 317 - Derivative liability - ELOC commitment note 347 - Common stock warrant liability 8,621 - Loans payable 444 233 Other current liabilities 525 900 Total current liabilities 14,426 3,996 Operating lease liabilities - non-current portion 784 1,161 Restructured debt liability - contingent milestone payments - 15,000 Other liabilities 3,800 3,800 Deferred tax liabilities 4,887 5,058 Total liabilities 23,897 29,015 Mezzanine Equity: Series C redeemable preferred stock, $0.001 par value; 18,820 and 0 shares authorized; 15,719 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 2,142 - Series B redeemable preferred stock, $0.001 par value; 5,500 and 0 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Total mezzanine equity 2,142 - Stockholders' Equity: Preferred stock, $0.001 par value; 4,975,680 and 5,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Common stock, $0.001 par value; 120,000,000 shares authorized; 2,340,429 and 333,145 shares issued at September 30, 2024 and December 31, 2023, respectively; 2,340,428 and 333,144 shares outstanding at September 30, 2024 and December 31, 2023, respectively 2 - Additional paid-in capital 856,267 851,268 Accumulated deficit (848,806 ) (844,823 ) Treasury stock (at cost); 1 share (3,054 ) (3,054 ) Total stockholders' equity 4,409 3,391 Total liabilities, mezzanine equity & stockholders' equity $ 30,448 $ 32,406 WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Expenses: Research and development $ 1,968 $ 2,110 $ 14,084 $ 5,288 General and administrative 2,773 2,580 6,514 7,292 Loss on impairment of goodwill - - - 3,058 Total operating expenses 4,741 4,690 20,598 15,638 Operating loss (4,741 ) (4,690 ) (20,598 ) (15,638 ) Other income (expense): Gain on debt extinguishment 71 - 14,591 - Change in fair value of common stock warrant liability 2,166 - 2,166 - Interest income 12 112 62 264 Interest expense (51 ) (13 ) (174 ) (38 ) Other (expense) income, net (446 ) 166 (530 ) 275 Total other income, net 1,752 265 16,115 501 Loss before income taxes (2,989 ) (4,425 ) (4,483 ) (15,137 ) Income tax benefit (expense) 240 - (71 ) - Net loss $ (2,749 ) $ (4,425 ) $ (4,554 ) $ (15,137 ) Extinguishment of Series B Preferred Stock 572 - 572 - Deemed dividend on Series C Preferred Stock (1,573 ) - (1,573 ) - Net loss attributable to common stockholders $ (3,750 ) $ (4,425 ) $ (5,555 ) $ (15,137 ) Net loss per share attributable to common stockholders Basic and diluted $ (4.23 ) $ (15.47 ) $ (8.64 ) $ (80.95 ) Weighted average number of common shares outstanding Basic and diluted 887 286 643 187 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Debenhams drops 40% off 'fabulous' £261 shower tower described as a 'splendid bit of kit'Semona scores 15 as Stonehill takes down Lafayette 70-65Clara Strack and Georgia Amoore each scored 21 points on Saturday to help No. 16 Kentucky beat visiting Western Kentucky 88-70 in Lexington. Teonni Key netted 15 points, Amelia Hassett paired nine points with 12 rebounds and Saniah Tyler scored 11 off the bench for the Wildcats (11-1), who won their fourth straight game. The Lady Toppers (9-3) got 18 points from Alexis Mead, 14 from Acacia Hayes, 11 from Destiny Salary and 10 from Josie Gilvin. Western Kentucky has lost three of five following a 7-0 start. Kentucky used a 9-0 run in the second quarter to take a double-digit lead that it held for the rest of the game. Strack bookended the surge with a layup and a 3-pointer that pushed the hosts ahead 36-22 with 1:01 remaining in the first half. The Wildcats' lead peaked at 23 points after Amoore scored five straight late in the fourth quarter to make it 88-65. Saturday marked the final nonconference game for both teams this season. Kentucky hosts Mississippi State to begin Southeastern Conference play on Thursday, while Western Kentucky starts its Conference USA slate by hosting Liberty the same night. --Field Level Media
Legislators greenlight reforms giving more authority to Daniel Ortega and Rosario Murillo, accused of stifling dissent. Legislators in Nicaragua have approved a constitutional amendment that will strengthen the power of longtime President Daniel Ortega, who has been accused of cracking down on critics and political challengers. The reforms, which 79-year-old Ortega sent to Congress this week “as a matter of urgency”, were approved unanimously on Friday by 91 lawmakers. The changes elevate Ortega’s wife and vice president, Rosario Murillo , to the post of “co-president”. They also increase the presidential term in the Central American nation from five to six years and extend the executive’s control over the media. According to the Nicaraguan Constitution, reforms must be approved in a second legislative period, in this case in 2025, before they become effective. Rights groups and international observers slammed the vote as a “sham” and accused the Sandinista leader of stifling dissent by trying to legalise the “absolute power” Ortega and his wife already wield in the country. “The reform not only reflects the paranoia and insecurity of the Sandinista dictatorship, but also codifies a system that has no exact precedent in Latin America, dangerously resembling the North Korean model,” wrote exiled opposition leader, Felix Maradiaga, in the online media outlet Divergentes. “These modifications reflect a desperate attempt to shield the Ortega-Murillo family from any eventuality,” he added. Decades in power Ortega first served as president from 1985 to 1990, returning to power in 2007. He secured a fourth consecutive term as president in 2021 after an election campaign that was marked by a months-long crackdown on dissent and the arrests of dozens of opposition figures, including several presidential hopefuls. Ortega’s government has shut down more than 5,000 NGOs since mass protests broke out against his rule in 2018. About 300 people died in the unrest, according to the United Nations. Meanwhile, thousands of Nicaraguans have fled into exile — often to neighbouring Costa Rica — and the United States and European Union have imposed a series of sanctions against Ortega’s administration. “Nicaragua is being stripped of its intellectual capital and critical voices,” a UN panel warned last year. Friday’s constitutional amendment stipulates that “traitors to the homeland” can be stripped of their citizenship – something Ortega has already done with hundreds of politicians, journalists, intellectuals and activists perceived as critical of his government. It also gives the co-presidents the power to coordinate all “legislative, judicial, electoral, control and supervisory bodies, regional and municipal”. The Organization of American States, a regional body, has slammed the reforms as “a definitive attack on the democratic rule of law”. “Through these modifications to the fundamental law, Ortega and his allies seek to increase their absolute control of the State and perpetuate themselves in power,” the group said in a statement on Wednesday.
The top 10 football teams in Maine as voted on by reporters from the Press Herald, Kennebec Journal/Morning Sentinel, Sun Journal and Forecaster, with first-place votes in parentheses, followed by total points. Through games of 11/23/24 Comments are not available on this story. Send questions/comments to the editors. « PreviousArsenal, Man City and Bayern advance to Women's Champions League quarterfinals
Stunning rally in Big Tech drives Nasdaq to 20,000ORONO, Maine (AP) — Michael McNair scored 16 points to lead Boston University and Malcolm Chimezie sealed the victory with a layup with 20 seconds left as the Terriers took down Maine 59-56 on Sunday. McNair also had six rebounds for the Terriers (6-7). Kyrone Alexander scored 13 points and added five rebounds. Chimezie shot 4 of 7 from the field and 0 for 3 from the line to finish with eight points. Kellen Tynes led the way for the Black Bears (8-7) with 17 points, four assists and three steals. Maine also got 12 points from Christopher Mantis. Quion Burns had eight points. McNair scored seven points in the first half and Boston University went into halftime trailing 27-19. Alexander scored a team-high 10 points for Boston University in the second half. Boston University outscored Maine by 11 points over the final half. Boston University's next game is Thursday against Lafayette on the road, and Maine visits Bryant on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Ensuring a reliable supply of critical battery raw materials will be crucial to the global push to net-zero, especially with demand for battery electric vehicles (BEV) picking up pace towards the end of this decade, a new report by McKinsey finds. By 2030, McKinsey estimates that worldwide demand for passenger cars in the BEV segment will grow sixfold from 2021 through 2030, with annual unit sales increasing to roughly 28 million from 4.5 million during that period. Such a projection, the consultancy says, means that the industry is “likely to confront persistent long-term challenges” in keeping with demand. In particular, its reports highlights that automotive OEMs are giving more attention to reducing Scope 3 emissions from material usage, which contribute a large portion of what batteries emit. As a result, battery materials sourcing has become ever more important for battery producers. Based on the latest estimates, McKinsey’s analysis projects that demand will outpace base-case supply for certain materials, requiring additional investment and leading to fear of shortages and price volatility, among other challenges. Supply shortages looming Based on current market observations, battery manufacturers can expect challenges securing supply of several essential battery raw materials by 2030, McKinsey’s report finds. Battery makers use more than 80% of all lithium that is mined today, and that share could grow to 95% by 2030. With technological advancements shifting in favor of lithium-heavy batteries, lithium mining will need to increase substantially to meet 2030 demand, McKinsey says. For nickel, fears of a shortage prompted by the shift to BEVs have already triggered significant investments in new mines, particularly in Southeast Asia, but even more supply will need to be brought online. McKinsey’s report suggests the possibility of a slight shortage in 2030 as the battery sector continues to vie with steel and other sectors for Class 1 nickel. While the share of cobalt in battery chemistry mix is expected to decrease, the absolute demand for cobalt for all applications could rise by 7.5% a year from 2023 and 2030, McKinsey estimates, adding that shortages of cobalt are unlikely, but its supply will be driven by nickel and copper since it is largely a byproduct of their production. Meanwhile, the supply of manganese is projected to grow moderately through 2030, but an increasing demand for battery-grade material is likely to outpace supply, requiring the development of new refineries. To account for a rapid adoption of LFP (lithium iron phosphate) technology, McKinsey’s study models the 2030 supply and demand balances with two scenarios. Under the base case, only about 20% of the HPMSM (high-purity manganese sulfate monohydrate) supply will meet the requirements of battery applications (30% if all announced projects are realized), which themselves will account for only about 5% of total demand for manganese. In a world where the rapid adoption of LFP technology is coupled with a lower growth in EV production, the demand of battery materials could look different: Global trends Although overall demand for batteries and raw materials is increasing rapidly, supply is — and will remain — largely concentrated in a few naturally endowed countries, including Indonesia for nickel; Argentina, Bolivia, and Chile for lithium; and the DRC for cobalt, McKinsey says. Meanwhile, the refining typically takes place elsewhere, often in China (for cobalt and lithium), Indonesia (nickel), and Brazil (niobium). This value chain setup, according to McKinsey, poses additional considerations for regions such as the European Union and the United States, both of which have high demand for imported materials and often rely heavily on single-country sources. For example, the European Union imports 68% of its cobalt from the DRC, 24% of its nickel from Canada, and 79% of its refined lithium from Chile. Supply chain transparency Moreover, although supply concentration for materials such as refined nickel, cobalt and lithium are knowable, complete visibility into the origin of raw materials is sometimes unattainable. This is the case with high-purity manganese, of which more than 95% is produced in China and minor volumes come from Belgium and Japan; graphite, of which almost all is refined in China; and anode production, on which China has a near monopoly. Limited transparency into the origins of battery raw materials supply also poses broader ESG concerns and attention. For instance, the EU Batteries Regulation aims to make batteries sustainable throughout their entire life cycle, from material sourcing to battery collection, recycling and repurposing. As a result, McKinsey believes the pressure to address ESG concerns will likely increase moving forward. Recent supply chain disruptions, such as those affecting magnesium, silicon and semiconductors in from 2021 to 2023, have increased buyers’ needs to boost supply chain resilience for critical battery raw materials. Buyers’ risks of import dependency are further heightened by recent trade restrictions introduced by exporters, including China’s export controls on some materials (such as synthetic graphite and natural flake graphite products used in BEVs) and Indonesia’s ban on nickel ore exports.
- Previous: sg777 casino
- Next: ph777 app
